Overview

Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors

Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label, dose escalation, study of the combination of cisplatin and OSI-7904L given on Day 1 every 21 days in patient who have advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
OSI Pharmaceuticals
Treatments:
Cisplatin